LT3398B - Process for preparing deacylated 10-baccatine iii - Google Patents
Process for preparing deacylated 10-baccatine iii Download PDFInfo
- Publication number
- LT3398B LT3398B LTIP1397A LTIP1397A LT3398B LT 3398 B LT3398 B LT 3398B LT IP1397 A LTIP1397 A LT IP1397A LT IP1397 A LTIP1397 A LT IP1397A LT 3398 B LT3398 B LT 3398B
- Authority
- LT
- Lithuania
- Prior art keywords
- process according
- deacetyl
- ether
- baccatin iii
- butyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 claims abstract description 47
- 241001116500 Taxus Species 0.000 claims abstract description 37
- 241000196324 Embryophyta Species 0.000 claims abstract description 9
- 239000000401 methanolic extract Substances 0.000 claims abstract description 8
- 241001116498 Taxus baccata Species 0.000 claims abstract description 6
- 238000010956 selective crystallization Methods 0.000 claims abstract description 5
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 claims description 113
- 229930014667 baccatin III Natural products 0.000 claims description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 34
- 239000003960 organic solvent Substances 0.000 claims description 22
- 239000012675 alcoholic extract Substances 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- -1 aliphatic ethers Chemical class 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 17
- 229930012538 Paclitaxel Natural products 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- 229960001592 paclitaxel Drugs 0.000 claims description 14
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 239000012071 phase Substances 0.000 claims description 12
- 238000010908 decantation Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 7
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical group CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 claims description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 6
- 229940011051 isopropyl acetate Drugs 0.000 claims description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 6
- 229940063683 taxotere Drugs 0.000 claims description 6
- NUMQCACRALPSHD-UHFFFAOYSA-N tert-butyl ethyl ether Chemical compound CCOC(C)(C)C NUMQCACRALPSHD-UHFFFAOYSA-N 0.000 claims description 6
- 241000202349 Taxus brevifolia Species 0.000 claims description 5
- 235000009065 Taxus cuspidata Nutrition 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- GPDFVOVLOXMSBT-UHFFFAOYSA-N 1-propan-2-yloxybutane Chemical compound CCCCOC(C)C GPDFVOVLOXMSBT-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- 229940072049 amyl acetate Drugs 0.000 claims description 4
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 claims description 4
- 229940093499 ethyl acetate Drugs 0.000 claims description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 4
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 229940090181 propyl acetate Drugs 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 238000010257 thawing Methods 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- RQUBQBFVDOLUKC-UHFFFAOYSA-N 1-ethoxy-2-methylpropane Chemical compound CCOCC(C)C RQUBQBFVDOLUKC-UHFFFAOYSA-N 0.000 claims description 3
- 241000015728 Taxus canadensis Species 0.000 claims description 3
- 241000013869 Taxus floridana Species 0.000 claims description 3
- 241001330449 Taxus wallichiana Species 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- ZXHQLEQLZPJIFG-UHFFFAOYSA-N 1-ethoxyhexane Chemical compound CCCCCCOCC ZXHQLEQLZPJIFG-UHFFFAOYSA-N 0.000 claims description 2
- BPIUIOXAFBGMNB-UHFFFAOYSA-N 1-hexoxyhexane Chemical compound CCCCCCOCCCCCC BPIUIOXAFBGMNB-UHFFFAOYSA-N 0.000 claims description 2
- HFZLSTDPRQSZCQ-UHFFFAOYSA-N 1-pyrrolidin-3-ylpyrrolidine Chemical compound C1CCCN1C1CNCC1 HFZLSTDPRQSZCQ-UHFFFAOYSA-N 0.000 claims description 2
- FITVQUMLGWRKKG-UHFFFAOYSA-N 2-methyl-2-propoxypropane Chemical compound CCCOC(C)(C)C FITVQUMLGWRKKG-UHFFFAOYSA-N 0.000 claims description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 238000010981 drying operation Methods 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- KFRVYYGHSPLXSZ-UHFFFAOYSA-N 2-ethoxy-2-methylbutane Chemical compound CCOC(C)(C)CC KFRVYYGHSPLXSZ-UHFFFAOYSA-N 0.000 claims 2
- 229930190007 Baccatin Natural products 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims 2
- DXBOTVWRXLQVMG-UHFFFAOYSA-N methyl 3,3-dimethylbutanoate Chemical compound COC(=O)CC(C)(C)C DXBOTVWRXLQVMG-UHFFFAOYSA-N 0.000 claims 1
- JAELLLITIZHOGQ-UHFFFAOYSA-N tert-butyl propanoate Chemical compound CCC(=O)OC(C)(C)C JAELLLITIZHOGQ-UHFFFAOYSA-N 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 5
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 2
- 241001674343 Taxus x media Species 0.000 description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PZHIWRCQKBBTOW-UHFFFAOYSA-N 1-ethoxybutane Chemical compound CCCCOCC PZHIWRCQKBBTOW-UHFFFAOYSA-N 0.000 description 1
- VDMXPMYSWFDBJB-UHFFFAOYSA-N 1-ethoxypentane Chemical compound CCCCCOCC VDMXPMYSWFDBJB-UHFFFAOYSA-N 0.000 description 1
- AOPDRZXCEAKHHW-UHFFFAOYSA-N 1-pentoxypentane Chemical compound CCCCCOCCCCC AOPDRZXCEAKHHW-UHFFFAOYSA-N 0.000 description 1
- ZLRFPQPVXRIBCQ-UHFFFAOYSA-N 2-$l^{1}-oxidanyl-2-methylpropane Chemical group CC(C)(C)[O] ZLRFPQPVXRIBCQ-UHFFFAOYSA-N 0.000 description 1
- LUMNWCHHXDUKFI-UHFFFAOYSA-N 5-bicyclo[2.2.1]hept-2-enylmethanol Chemical compound C1C2C(CO)CC1C=C2 LUMNWCHHXDUKFI-UHFFFAOYSA-N 0.000 description 1
- DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Fats And Perfumes (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9211746A FR2696463B1 (fr) | 1992-10-05 | 1992-10-05 | Procédé d'obtention de la désacétyl-10 baccatine III. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP1397A LTIP1397A (en) | 1994-11-25 |
| LT3398B true LT3398B (en) | 1995-09-25 |
Family
ID=9434124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP1397A LT3398B (en) | 1992-10-05 | 1993-10-04 | Process for preparing deacylated 10-baccatine iii |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5393895A (enExample) |
| EP (1) | EP0663910B1 (enExample) |
| JP (1) | JP3299754B2 (enExample) |
| KR (1) | KR100301236B1 (enExample) |
| CN (1) | CN1043530C (enExample) |
| AT (1) | ATE148883T1 (enExample) |
| AU (1) | AU680629B2 (enExample) |
| CA (1) | CA2146373C (enExample) |
| CZ (2) | CZ284615B6 (enExample) |
| DE (1) | DE69308155T2 (enExample) |
| DK (1) | DK0663910T3 (enExample) |
| EE (1) | EE03126B1 (enExample) |
| ES (1) | ES2098061T3 (enExample) |
| FI (1) | FI109794B (enExample) |
| FR (1) | FR2696463B1 (enExample) |
| GE (1) | GEP20001937B (enExample) |
| GR (1) | GR3022617T3 (enExample) |
| HU (1) | HU226862B1 (enExample) |
| LT (1) | LT3398B (enExample) |
| LV (1) | LV10621B (enExample) |
| MX (1) | MX9305771A (enExample) |
| NO (1) | NO310413B1 (enExample) |
| NZ (1) | NZ256450A (enExample) |
| PL (1) | PL177316B1 (enExample) |
| RU (1) | RU2107065C1 (enExample) |
| SK (1) | SK280949B6 (enExample) |
| TW (1) | TW255890B (enExample) |
| UA (1) | UA44227C2 (enExample) |
| WO (1) | WO1994007882A1 (enExample) |
| ZA (1) | ZA937313B (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2696462B1 (fr) * | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| CA2472404A1 (en) | 1993-07-19 | 1995-02-02 | Angiotech Pharmaceuticals, Inc. | Combination of stent and anti-angiogenic factor |
| CA2165825A1 (en) * | 1993-11-02 | 1995-05-11 | Bernhard Ulbrich | Method and device for the separation of a mixture |
| FR2714053B1 (fr) * | 1993-12-22 | 1996-03-08 | Pf Medicament | Procédé d'extraction et d'isolement de la 10-désacétylbaccatine III. |
| CN1112433A (zh) * | 1994-05-24 | 1995-11-29 | 郭明 | 红豆杉属植物提取物及其应用 |
| AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
| FR2736355B1 (fr) * | 1995-07-07 | 1997-11-07 | Pf Medicament | Procede d'extraction et d'isolement de la 10-desacetylbaccatine iii |
| US5750736A (en) * | 1996-07-11 | 1998-05-12 | Napro Biotherapeutics, Inc. | Method for acylating 10-deacetylbaccatin III selectively at the c-10 position |
| US5965752A (en) * | 1996-08-23 | 1999-10-12 | Institut National De La Recherche Scientifique | Preparative scale isolation and purification of taxanes |
| US6111144A (en) | 1997-08-21 | 2000-08-29 | Florida State University | Method for the synthesis of a taxane intermediate |
| US6002024A (en) * | 1998-07-27 | 1999-12-14 | Dabur Research Foundation | Process for the isolation of 14β-hydroxy-10-deacetyl baccatin-III |
| US6136989A (en) * | 1998-12-30 | 2000-10-24 | Phytogen Life Sciences, Incorporated | Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material |
| US6281368B1 (en) | 2000-03-16 | 2001-08-28 | Napro Biotherapeutics, Inc. | Simple and efficient hydrazinolysis of C-10 and C-13 ester functionalities of taxanes to obtain 10-DAB III |
| US6495705B2 (en) | 2000-03-16 | 2002-12-17 | Napro Biotherapeutics, Inc. | Efficient process for the production of 10-DAB III by selective hydrazinolysis of various taxanes |
| CA2307393A1 (en) | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
| US20030157170A1 (en) * | 2001-03-13 | 2003-08-21 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
| CA2440935A1 (en) | 2001-03-13 | 2002-09-19 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
| DE60220519T2 (de) * | 2001-04-20 | 2007-09-27 | The University Of British Columbia, Vancouver | Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| CA2525647A1 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| US7989490B2 (en) | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
| US7846940B2 (en) | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
| US8003122B2 (en) | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| DE602005012587D1 (de) * | 2004-07-02 | 2009-03-19 | Ivax Pharmaceuticals Sro | Verfahren zur trennung von paclitaxel und cephalomannin |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| US8691780B2 (en) | 2005-02-17 | 2014-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby |
| WO2007062036A2 (en) | 2005-11-21 | 2007-05-31 | Med Institute, Inc. | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent |
| BRPI0709075A2 (pt) | 2006-03-20 | 2011-10-11 | Medigene Ag | tratamento de cáncer de mama triplo receptor negativo |
| WO2008005284A2 (en) | 2006-06-30 | 2008-01-10 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
| US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
| US8420110B2 (en) | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
| US8273404B2 (en) | 2008-05-19 | 2012-09-25 | Cordis Corporation | Extraction of solvents from drug containing polymer reservoirs |
| EP2296645B1 (en) | 2008-05-22 | 2014-11-19 | Galera Therapeutics, LLC | Combination antitumor therapy |
| EP2310507A4 (en) | 2008-07-08 | 2013-03-20 | David Gladstone Inst | METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION |
| US8642063B2 (en) | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
| US20120302954A1 (en) | 2011-05-25 | 2012-11-29 | Zhao Jonathon Z | Expandable devices coated with a paclitaxel composition |
| US20120303115A1 (en) | 2011-05-25 | 2012-11-29 | Dadino Ronald C | Expandable devices coated with a rapamycin composition |
| WO2013069027A1 (en) | 2011-09-26 | 2013-05-16 | Fresenius Kabi Oncology Ltd. | Processes for the preparation of cabazitaxel involving c(7) -oh and c(13) -oh silylation or just c(7) -oh silylation |
| US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
| EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
| AU2013341711A1 (en) | 2012-11-12 | 2015-05-21 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| CN103804326A (zh) * | 2012-11-15 | 2014-05-21 | 刘胜远 | 一种从含10-去乙酰基巴卡亭ⅲ的浸膏分离和提纯10-去乙酰基巴卡亭ⅲ的方法 |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| CN103145652B (zh) * | 2013-03-05 | 2015-09-30 | 无锡尔云科技有限公司 | 一种从红豆杉属植物中提取紫杉醇及其衍生物的方法 |
| WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| CN115504924A (zh) | 2013-11-27 | 2022-12-23 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
| HUE051255T2 (hu) | 2014-02-19 | 2021-03-01 | Aviv Therapeutics Inc | Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére |
| AU2016326747A1 (en) | 2015-09-25 | 2018-03-01 | Zy Therapeutics Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
| US10654875B2 (en) | 2015-11-12 | 2020-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
| TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
| JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール．ピー．シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
| CN109640961B (zh) | 2016-06-01 | 2021-11-02 | 施维雅知识产权英国有限公司 | 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法 |
| TWI852903B (zh) | 2017-01-05 | 2024-08-21 | 杏國新藥股份有限公司 | 胰臟癌治療 |
| JP7280827B2 (ja) | 2017-01-18 | 2023-05-24 | エクスマ バイオテック コーポレイション | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
| EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| WO2018218004A1 (en) | 2017-05-24 | 2018-11-29 | The Board Of Regents Of The University Of Texas System | Linkers for antibody drug conjugates |
| CA3090129A1 (en) | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
| CA3096202A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| CA3095757A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating glioblastomas |
| BR112020020930A2 (pt) | 2018-04-11 | 2021-03-02 | Ohio State Innovation Foundation | composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit |
| CN108904137A (zh) * | 2018-05-27 | 2018-11-30 | 肖军威 | 一种卫生巾芯片的制备方法及卫生巾芯片的加工设备 |
| CA3105879A1 (en) | 2018-07-18 | 2020-01-23 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
| TW202038994A (zh) | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| WO2020165730A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| JP7716623B2 (ja) | 2019-04-02 | 2025-08-01 | ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 | 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法 |
| CN110317183B (zh) * | 2019-08-08 | 2021-03-12 | 无锡紫杉药业有限公司 | 一种红豆杉天然提取产物的纯化方法 |
| WO2021116943A1 (en) | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| WO2021155028A1 (en) | 2020-01-29 | 2021-08-05 | Kenjockety Biotechnology, Inc. | Anti-mdr1 antibodies and uses thereof |
| CN116529267A (zh) | 2020-06-04 | 2023-08-01 | 肯乔克蒂生物技术股份有限公司 | Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法 |
| WO2021247426A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
| AU2021310520A1 (en) | 2020-07-14 | 2023-02-16 | Pfizer Inc. | Recombinant vaccinia virus |
| CA3193588A1 (en) | 2020-09-02 | 2022-03-10 | Kenjockety Biotechnology, Inc. | Anti-abcc1 antibodies and uses thereof |
| WO2022103603A1 (en) | 2020-11-13 | 2022-05-19 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
| US12187810B2 (en) | 2020-11-20 | 2025-01-07 | R.P. Scherer Technologies, Llc | Glycoside dual-cleavage linkers for antibody-drug conjugates |
| CN112694458A (zh) * | 2020-12-29 | 2021-04-23 | 重庆臻源红豆杉发展有限公司 | 一种10-去乙酰基巴卡亭ⅲ提取纯化方法 |
| US20250051471A1 (en) | 2021-12-13 | 2025-02-13 | William Robert Arathoon Living Trust Dated August 29, 2016 | Anti-Abcb1 Antibodies |
| WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814470A (en) | 1986-07-17 | 1989-03-21 | Rhone-Poulenc Sante | Taxol derivatives, their preparation and pharmaceutical compositions containing them |
| US4924011A (en) | 1988-04-06 | 1990-05-08 | Centre National De La Recherche Scientifique | Process for preparing taxol |
| US4924012A (en) | 1988-04-06 | 1990-05-08 | Rhone-Poulenc Sante | Process for preparing derivatives of baccatine III and of 10-deacetyl baccatine III |
| EP0400971A2 (en) | 1989-05-31 | 1990-12-05 | Florida State University | Method for preparation of taxol |
| EP0428376A1 (en) | 1989-11-14 | 1991-05-22 | Florida State University | Method for preparation of taxol using an oxazinone |
| WO1992009589A1 (fr) | 1990-11-23 | 1992-06-11 | Rhone-Poulenc Rorer S.A. | Procede de preparation de derives du taxane, nouveaux derives obtenus et compositions pharmaceutiques qui les contiennent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380916A (en) | 1990-11-02 | 1995-01-10 | University Of Florida | Method for the isolation and purification of taxane derivatives |
| EP0580759B1 (en) * | 1991-04-19 | 1999-05-26 | The University Of Mississippi | Methods and compositions for isolating taxanes |
| IT1258838B (it) * | 1992-01-31 | 1996-02-29 | Indena Spa | Processo per l'estrazione di tassolo e derivati da cultivar del genere taxus |
-
1992
- 1992-10-05 FR FR9211746A patent/FR2696463B1/fr not_active Expired - Lifetime
-
1993
- 1993-01-27 US US08/010,083 patent/US5393895A/en not_active Expired - Lifetime
- 1993-04-10 UA UA95038244A patent/UA44227C2/uk unknown
- 1993-04-21 CN CN93104616A patent/CN1043530C/zh not_active Expired - Lifetime
- 1993-09-21 MX MX9305771A patent/MX9305771A/es unknown
- 1993-10-01 ZA ZA937313A patent/ZA937313B/xx unknown
- 1993-10-02 TW TW082108103A patent/TW255890B/zh not_active IP Right Cessation
- 1993-10-04 ES ES93921987T patent/ES2098061T3/es not_active Expired - Lifetime
- 1993-10-04 DK DK93921987.9T patent/DK0663910T3/da active
- 1993-10-04 LV LVP-93-1120A patent/LV10621B/xx unknown
- 1993-10-04 SK SK433-95A patent/SK280949B6/sk not_active IP Right Cessation
- 1993-10-04 DE DE69308155T patent/DE69308155T2/de not_active Expired - Lifetime
- 1993-10-04 JP JP50879294A patent/JP3299754B2/ja not_active Expired - Lifetime
- 1993-10-04 LT LTIP1397A patent/LT3398B/lt not_active IP Right Cessation
- 1993-10-04 HU HU9500973A patent/HU226862B1/hu unknown
- 1993-10-04 GE GEAP19932511A patent/GEP20001937B/en unknown
- 1993-10-04 WO PCT/FR1993/000972 patent/WO1994007882A1/fr not_active Ceased
- 1993-10-04 CZ CZ95845A patent/CZ284615B6/cs not_active IP Right Cessation
- 1993-10-04 AT AT93921987T patent/ATE148883T1/de active
- 1993-10-04 PL PL93308244A patent/PL177316B1/pl unknown
- 1993-10-04 AU AU51155/93A patent/AU680629B2/en not_active Expired
- 1993-10-04 EP EP93921987A patent/EP0663910B1/fr not_active Expired - Lifetime
- 1993-10-04 NZ NZ256450A patent/NZ256450A/en not_active IP Right Cessation
- 1993-10-04 CA CA002146373A patent/CA2146373C/fr not_active Expired - Lifetime
- 1993-10-04 RU RU95110687/04A patent/RU2107065C1/ru active
- 1993-10-04 KR KR1019950701306A patent/KR100301236B1/ko not_active Expired - Lifetime
-
1994
- 1994-11-18 EE EE9400364A patent/EE03126B1/xx unknown
-
1995
- 1995-04-03 NO NO19951282A patent/NO310413B1/no not_active IP Right Cessation
- 1995-04-04 FI FI951596A patent/FI109794B/fi not_active IP Right Cessation
-
1997
- 1997-02-20 GR GR960402767T patent/GR3022617T3/el unknown
-
1998
- 1998-02-06 CZ CZ1998367A patent/CZ287065B6/cs not_active IP Right Cessation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814470A (en) | 1986-07-17 | 1989-03-21 | Rhone-Poulenc Sante | Taxol derivatives, their preparation and pharmaceutical compositions containing them |
| US4924011A (en) | 1988-04-06 | 1990-05-08 | Centre National De La Recherche Scientifique | Process for preparing taxol |
| US4924012A (en) | 1988-04-06 | 1990-05-08 | Rhone-Poulenc Sante | Process for preparing derivatives of baccatine III and of 10-deacetyl baccatine III |
| EP0400971A2 (en) | 1989-05-31 | 1990-12-05 | Florida State University | Method for preparation of taxol |
| EP0428376A1 (en) | 1989-11-14 | 1991-05-22 | Florida State University | Method for preparation of taxol using an oxazinone |
| WO1992009589A1 (fr) | 1990-11-23 | 1992-06-11 | Rhone-Poulenc Rorer S.A. | Procede de preparation de derives du taxane, nouveaux derives obtenus et compositions pharmaceutiques qui les contiennent |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3398B (en) | Process for preparing deacylated 10-baccatine iii | |
| US5393896A (en) | Process for obtaining 10-deacetylbaccatin III | |
| US5453521A (en) | Process for obtaining 10-deacetylbaccatin III | |
| EP1010697B1 (en) | Process for isolation of 14-b hydroxy-10-deacetyl baccatin-III | |
| US6124482A (en) | Process for isolation of 10-deacetyl baccatin-III | |
| KR960037669A (ko) | 결정화에 의한 택서스속 식물체로부터 택솔의 정제방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD9A | Change of patent owner |
Owner name: AVENTIS PHARMA S.A., FR Effective date: 20041206 |
|
| MK9A | Expiry of a patent |
Effective date: 20131004 |